MyMD Pharmaceuticals, Inc. (MYMD)

MyMD Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	2.68	0.75	0.56	0.15	0.52
Short-Term Investments	2.24	4.09	11	0	9.16
Cash & Cash Equivalents	4.92	4.84	11.56	0.15	9.68
Cash Growth	1.80%	-58.16%	7695.20%	-98.47%	77.49%
Other Current Assets	0.89	0.57	1.11	0	0.63
Total Current Assets	5.82	5.4	12.67	0.15	10.31
Property, Plant & Equipment	0.05	0.14	0.15	0.53	0
Long-Term Investments	1.5	1.5	1.5	0	0.12
Goodwill and Intangibles	10.5	10.5	10.5	0	0
Other Long-Term Assets	0	0	0	0	0.46
Total Long-Term Assets	12.05	12.14	12.15	0.53	0.57
Total Assets	17.86	17.54	24.81	0.68	10.88
Accounts Payable	3.72	2.67	0.99	1.8	0.89
Current Debt	0.05	0.07	0.05	0.55	0
Other Current Liabilities	1.22	0.03	0	0	0.64
Total Current Liabilities	4.99	2.77	1.04	2.35	1.53
Long-Term Debt	0	0.08	0.1	3.59	0
Other Long-Term Liabilities	0.1	0	0.03	0	0
Total Long-Term Liabilities	0.1	0.08	0.13	3.59	0
Total Liabilities	5.09	2.84	1.17	5.93	1.53
Total Debt	0.05	0.14	0.15	4.13	0
Debt Growth	-65.52%	-4.98%	-96.39%	-	-
Retained Earnings	-101.98	-93.76	-78.56	-48.67	-119.58
Comprehensive Income	0	0	0	0	0.02
Shareholders' Equity	12.37	14.7	23.65	-5.26	9.36
Net Cash / Debt	4.87	4.69	11.41	-3.98	9.68
Net Cash / Debt Growth	3.83%	-58.86%	-	-	77.49%
Net Cash Per Share	3.16	3.63	9.78	-4.24	948.17
Working Capital	0.83	2.63	11.63	-2.2	8.78
Book Value Per Share	8.02	11.36	20.26	-5.59	916.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).